A Dedicated Low-Cost Fluorescence Microfluidic Device Reader for Point-of-Care Ocular Diagnostics

Microfluidic fluorescence assay devices show great promise as preclinical and clinical diagnostic instruments. Normally, fluorescence signals from microfluidic chips are quantified by analysis of images obtained with a commercial fluorescence microscope. This method is unnecessarily expensive, time consuming, and requires significant operator training, particularly when considering future clinical translation of the technology. In this work, we developed a dedicated low cost fluorescence microfluidic device reader (FMDR) to read sandwich immunofluorescence assay (sIFA) devices configured to detect vascular endothelial growth factor ligand concentrations in ocular fluid samples. Using a series of sIFA calibration standards and a limited set of human ocular fluid samples, we demonstrated that our FMDR reader has similar sensitivity and accuracy to a fluorescence microscope for this task, with significantly lower total cost and reduced reading time. We anticipate that the reader could be used with minor modifications for virtually any fluorescence microfluidic device.

[1]  Quan Dong Nguyen,et al.  A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[2]  A. Schachat,et al.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  S Sivaprasad,et al.  Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature , 2010, Eye.

[4]  Vincent Linder,et al.  Microfluidics at the crossroad with point-of-care diagnostics. , 2007, The Analyst.

[5]  J. Caminal,et al.  INTRAVITREAL INFLIXIMAB IN PATIENTS WITH MACULAR DEGENERATION WHO ARE NONRESPONDERS TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2010, Retina.

[6]  R. Zengerle,et al.  Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. , 2010, Chemical Society reviews.

[7]  Matthias Bolz,et al.  ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMAB , 2010, Retina.

[8]  G. Whitesides The origins and the future of microfluidics , 2006, Nature.

[9]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[10]  J. Tombran-Tink,et al.  PEDF in angiogenic eye diseases. , 2010, Current molecular medicine.

[11]  P. Yager,et al.  Point-of-care diagnostics for global health. , 2008, Annual review of biomedical engineering.

[12]  James V. Green,et al.  Microfluidic pillar array sandwich immunofluorescence assay for ocular diagnostics , 2011, Biomedical microdevices.

[13]  M. Weger,et al.  Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab , 2009, Eye.

[14]  J. Vander,et al.  Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes , 2011 .